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Background: Dengue hemorrhagic fever is the leading cause of hospitalization and 
death in children living in Asia and Latin America. There is an urgent need for an effective 
and safe dengue vaccine to reduce morbidity and mortality in this high-risk population 
given the lack of dengue specific treatment at present. This review aims to determine the 
efficacy, safety, and immunogenicity of CYD-TDV vaccine in children.
Methods: This is a systematic review including meta-analysis of randomized controlled 
clinical trial data from Embase, Medline, the Cochrane Library, Web of Science, and 
ClinicalTrials.gov. Studies that assessed CYD-TDV vaccine efficacy [(1  −  RR)*100], 
safety (RR), and immunogenicity (weighted mean difference) in children were included in 
this study. Random effects model was employed to analyze patient-level data extracted 
from primary studies.
Results: The overall efficacy of CYD-TDV vaccine was 54% (40–64), while serotype- 
specific efficacy was 77% (66–85) for DENV4, 75% (65–82) for DENV3, 50% (36–61) for 
DENV1, and 34% (14–49) for DENV2. 15% (−174–74) vaccine efficacy was obtained 
for the unknown serotype. Meta-analysis of included studies with longer follow-up time 
(25 months) revealed that CYD-TDV vaccine significantly increased the risk of injection 
site reactions (RR = 1.1: 1.04–1.17; p-value = 0.001). Immunogenicity (expressed as 
geometric mean titers) in descending order was 439.7 (331.7–547.7), 323 (247 – 398.7), 
144.1 (117.9–170.2), and 105 (88.7–122.8) for DENV3, DENV2, DENV1, and DENV4, 
respectively.
Conclusion: CYD-TDV vaccine is effective and immunogenic in children overall. 
Reduced efficacy of CYD-TDV vaccine against DENV2 notoriously known for causing 
severe dengue infection and dengue outbreaks cause for serious concern. Post hoc 
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meta-analysis of long-term follow-up data (≥25  months) from children previously 
vaccinated with CYD-TDV vaccine is needed to make a conclusion regarding CYD-TDV 
vaccine safety in children. However, CYD-TDV vaccine should be considered for use 
in regions where DENV2 is not endemic as currently there is no specific treatment for 
dengue infection.
Keywords: dengue hemorrhagic fever, dengue shock syndrome, CYD-TDv, dengue virus, efficacy, safety, 
immunogenicity
A meta-analysis of randomized controlled trials (RCTs) by 
da Costa et al. has demonstrated that CYD-TDV vaccine is safe 
and induces a balanced immune response (16). However, safety 
and immunogenicity were determined for all age groups and 
no subgroup analysis based on the age of included participants 
was conducted. The fact that dengue infection is more severe in 
children compared to adults indicates that the two groups might 
respond to CYD-TDV vaccine differently with a possibility of 
adults confounding the true effect of the vaccine in children. The 
study also assessed vaccine efficacy by combining five primary 
studies. However, only Sabchareon et al. out of the five combined 
studies was designed to determine CYD-TDV vaccine efficacy in 
Thai children (17). The determined vaccine efficacy was 30.2% 
and was not statistically significant. Two large Phase III clinical 
studies designed to determine CYD-TDV vaccine efficacy and not 
included in the meta-analysis by da Costa et al. have been conducted 
in Asian and Latin American children showing efficacy of 56.5 and 
60.8%, respectively (9, 18). However, because these studies were 
conducted in various age groups from different regions, the find-
ings are not directly comparable. Therefore, to comprehensively 
address all the aforementioned concerns, we decided to determine 
the efficacy, safety, and immunogenicity of CYD-TDV vaccine in 
children by answering the following questions: (i) does CYD-TDV 
vaccine reduce the incidence of virologically confirmed dengue 
(VCD) cases in vaccinated compared with unvaccinated children? 
(ii) Does CYD-TDV vaccine increase the risk of adverse events in 
vaccinated as compared to the unvaccinated children? (iii) Is there 
a difference in geometric mean titers (GMTs) between children 
exposed to CYD-TDV vaccine and those unexposed?
MeTHODS
eligibility Criteria and Definitions
This review was conducted and reported in accordance with the 
Cochrane and preferred reporting items for systematic reviews 
and meta-analyses guidelines (19, 20). Population: children 
were defined as all individuals under the age of 18  years (21). 
Intervention: CYD-TDV vaccine manufactured by Sanofi 
Pasteur. Vaccine was reconstituted in 0.4% sodium chloride and 
2.5% serum albumin. Comparator: standard of care, placebo, or 
no intervention. Outcome: the primary end assessing points were 
CYD-TDV vaccine efficacy in accordance with the “Guidelines 
for clinical trials of dengue vaccine in endemic areas” (22). 
Reduction in the incidence of VCD cases per protocol analysis. 
Safety: AEs—unfavorable medical occurrences that are not 
treatment related and ARs—those that might be treatment related 
Abbreviations: ADE, antibody-dependent enhancement; AE, adverse events; AR, 
adverse reactions; CYD-TDV, live-tetravalent dengue vaccine; DENV, dengue 
virus; DHF, dengue hemorrhagic fever; DSS, dengue shock syndrome; ELISA, 
enzyme-linked immunosorbent assay; GMT, geometric mean titre; JE, Japanese 
encephalitis; PRISMA, preferred reporting items for systematic reviews and 
meta-analyses; PRNT50, plaque reduction neutralisation test with a 50% plaque 
reduction threshold; RCT, randomized controlled trial; RR, relative risk; RT-PCR, 
reverse transcription polymerase chain reaction; SAE, severe adverse events; UAE, 
unsolicited adverse events; UN, United Nations; VCD, virologically confirmed 
dengue; WHO, World Health Organization; WMD, weighted mean difference; YF, 
yellow fever.
iNTRODUCTiON
Continuously increasing dengue virus (DENV) related morbid-
ity and mortality poses a serious threat to global public health 
and has exerted pressure on national health budgets of endemic 
countries. There are four types of genetically distinct dengue 
viruses (DENV 1–4) (1), all causing severe dengue infection 
(2, 3). Brady et  al. estimates that four billion people are at risk 
of acquiring dengue infection worldwide (4) with approximately 
284–528 million dengue cases being documented annually (5). 
Dengue hemorrhagic fever (DHF)/Dengue Shock Syndrome 
(DSS) comprise 500,000 to one million of these cases leading to 
over 20,000 fatalities mostly in children (6, 7). The goal of World 
Health Organization is to reduce dengue related morbidity and 
mortality by 2020 (8). Despite the availability of vector control 
programs, dengue infection has continued to rise globally (9) with 
significant economic burdens and might continue to do so in the 
future given the ongoing climate change. Introducing an effica-
cious and safe vaccine in endemic regions has the potential to 
reduce dengue related hospitalization and death in children due to 
severe dengue infection (DHF/DSS). The risk of developing DHF/
DSS during secondary infection is increased when an individual is 
exposed to a dengue serotype that is different from the one previ-
ously experienced (10). This occurs due to antibody-dependent 
enhancement (ADE) which involves low levels of cross-reactive 
neutralizing antibodies produced during primary dengue infec-
tion forming complexes with target cell receptors (3, 11, 12). 
Consequently enhancing the number of dengue-infected cells 
and viremia (3, 11, 12). Therefore, a tetravalent dengue vaccine 
capable of eliciting a balanced immune response against all four 
dengue serotypes is warranted if complications due to ADE are to 
be averted (11, 13, 14). CYD-TDV vaccine is the most advanced 
live attenuated tetravalent dengue vaccine (15). However, com-
prehensive evidence regarding CYD-TDV vaccine efficacy, safety, 
and immunogenicity in children exclusively is absent.
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(23). Immunogenicity: levels of dengue neutralizing antibodies 
expressed as GMTs and measured using plaque reduction neu-
tralisation test with a 50% plaque reduction threshold (PRNT50). 
More information on the PRNT50 test can be obtained in the 
“guidelines for plaque reduction neutralization testing of human 
antibodies to dengue viruses” (24). Study design: only RCTs were 
included in this review. CYD-TDV vaccination interval require-
ment was that immunizations be conducted at months 0, 6, and 
12 (three vaccine regimen). Exclusion criteria: studies which did 
not assess CYD-TDV vaccine efficacy, safety, or immunogenicity 
or did not use CYD-TDV vaccine; studies involving participants 
aged over 17 years; and studies that used non-RCT study designs, 
non-three vaccine regimen or a three vaccine regimen with a dif-
ferent vaccination interval.
Literature Search and Data extraction
A comprehensive search strategy was developed in collabora-
tion with an experienced medical librarian to identify recently 
published studies as presented in Appendix I (all referenced 
appendices are in the Supplementary Material). Embase, 
Medline, Web of Science, the Cochrane Library, ClinicalTrials.
gov, references of included studies, and authors served as sources 
for published data. Gray literature was not searched because it 
lacks quality control. The search for published data was initiated 
on 01/03/2016, concluded on 11/05/2016 and pilot tested accord-
ing to the method proposed by Long (25) (Appendix II, Figure 
1 in Supplementary Material). This was done to ensure that the 
analysis includes all relevant information and fit to achieve the 
goal of this study. Corresponding authors of primary studies 
were contacted to request for numerical data or clarifications 
in cases where data were incomplete or graphically presented 
(Appendix II, Figure 2 in Supplementary Material). Information 
was extracted based on individual patient-level data.
Data items and Summary Measures
Primary end points and their respective summary measures 
included: overall and serotype-specific CYD-TDV vaccine effi-
cacy (per protocol analysis), CYD-TDV safety [immediate AEs, 
severe adverse events (SAEs), solicited ARs, solicited injection 
site reactions (pain, erythema, and swelling), solicited systemic 
reactions (fever, headache, malaise, myalgia, and asthenia) and 
unsolicited adverse event (UAEs)]. Relative risk (RR) was the pre-
ferred summary measure for CYD-TDV efficacy [(1 − RR)*100] 
(17) and safety, whereas immunogenicity (measured as GMTs) 
was estimated using the weighted mean difference (WMD). 
Relative risk was defined as the ratio of incidence VCD cases in 
the CYD-TDV vaccine group divided by the ratio of incidence 
VCD cases in the unvaccinated group (26). Mean difference 
was defined as an absolute difference between the GMTs in the 
intervention and control groups.
Risk of Bias and Statistical Analysis
The Cochrane Handbook for Systematic Reviews of 
Interventions tool (27) was used in this analysis to assess the 
quality of each of the included studies. The risk of bias was 
assessed both at the study and the outcome levels. Evidence 
tables served as the starting point for data synthesis. The tables 
were reviewed as well as the forest plots to determine the pos-
sibility of combining data from studies in a meta-analysis. The 
I2 and Q statistics were used to formally check for the presence 
of heterogeneity and consequently determine whether the effect 
sizes should be pooled. Heterogeneity was classified as low, 
medium and high for I2 values corresponding to 25, 50, and 
75%, respectively (28). If heterogeneity was either low/medium 
or reduced to these levels after being resolved, the pooled effect 
sizes of outcomes were explored. However, if variations in the 
effect size between pooled studies remained high (I2 ≥  75%) 
after efforts to resolve heterogeneity, meta-analysis was not 
conducted. The heterogeneity was investigated using meta-
regression and subgroup analysis to explain its possible cause. 
The Cochrane Collaboration recommends that studies with 
divergent effect sizes from the rest should be excluded to resolve 
heterogeneity (27). The influence of individual studies on the 
overall effect size was formally investigated using meta-influ-
ence. Identified studies were removed systematically to reduce 
heterogeneity across the combined studies. Sensitivity analysis 
was performed to explore the robustness of the findings using 
the fixed effects model (Appendices III and IV in Supplementary 
Material). The random effects model was preferred because 
the true effect size may not be constant across all the included 
studies (29) given that they were conducted in different age 
groups, countries, regions, and ethnic groups. Extracted data 
were exported from Excel spreadsheet to STATA version 13.0, 
where all statistical analyses were conducted. Publication bias 
was explored by employing Harbord’s and Egger’s tests.
ReSULTS
336 articles were selected for this study. Embase, Medline, 
Web of Science, the Cochrane Library, and ClinicalTrials.gov 
yielded 104, 80, 53, 46, and 53 articles, respectively (Figure 1 
below). Duplicate studies were removed using Mendeley 
reference manager leaving 194 published articles for further 
analysis. Of these, 174 articles were removed based on titles 
and abstracts. After an in-depth review, additional eight arti-
cles were excluded, including a press release (30), an abstract 
(31), one paper used a two regimen vaccination protocol (32), 
two papers used different vaccines, Acambis (33) and PVRV 
(34), and one meta-analysis of RCTs previously mentioned 
(16). Also, two studies utilizing a different protocol of the 
vaccination regimen and vaccine reconstitution protocol were 
excluded (35, 36). At the end of the selection procedure, nine 
studies were found eligible for inclusion in meta-analysis (9, 
17, 18, 37–42) after one study was excluded (43) because it 
presented all data graphically.
A summary of the included studies’ characteristics is 
presented in Table 1. Additional study activities are presented 
in Appendix II, Table 1 in Supplementary Material. All three 
studies that assessed vaccine efficacy used reverse transcrip-
tion polymerase chain reaction and enzyme-linked immuno-
sorbent assay tests to confirm dengue cases. Six studies did 
not specify how information regarding CYD-TDV vaccine 
safety was collected, while four requested parents/guardians 
of participants to record safety profiles. PRNT50 was utilized 
FigURe 1 | Study selection process.
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by all included studies to determine immunogenicity. Details 
regarding the aforesaid are summarized in Appendix II, 
Table 2 in Supplementary Material. Quality assessment of eli-
gible studies is presented in Table 2. Regarding RR and WMD 
analyses the values of no difference were 1 and 0, respectively. 
Therefore, 95% confidence intervals (95% CI) that traversed 
1 regarding the former and 0 the latter were considered sta-
tistically insignificant (alpha > 0.05). This review considered 
three hypotheses: CYD-TDV vaccination does not reduce the 
incidence of VCD cases in children; CYD-TDV vaccination 
increases the risk of ARs in children; and there is no difference 
in GMT levels between vaccinated and unvaccinated children. 
Variables used in meta-regression and subgroup analyses 
included: gender, sample size, randomization ratio, blinding 
method, placebo type, age group, study location, RCT phase, 
and flavivirus (DENV, yellow fever, and Japanese encephalitis) 
seroprevalence at baseline.
CYD-TDv vaccine efficacy
The review found a statistically significant pooled overall CYD-
TDV vaccine efficacy of 54% (40–64; p-value < 0.001). This result 
implies that the vaccine reduces the risk of acquiring dengue 
infection in the intervention group relative to the control group 
by 54%. Serotype-specific efficacy showed that CYD-TDV vaccine 
was more effective against DENV4 (77%: 66–85; p-value < 0.001) 
and DENV3 (75%: 65–82; p-value <  0.001), while it was less 
effective against DENV1 (50%: 36–61; p-value < 0.001), DENV2 
(34%: 14–49; p-value =  0.002) and unknown DENV serotype 
(15%: −174–74; p-value = 0.79). There was convincing evidence 
to reject the pre-specified null hypothesis for all but the unknown 
TABLe 2 | Risk of bias assessment.
Reference Selection bias Blinding Attrition Reporting bias Other bias Researcher’s judgment
Randomization Concealment Performance Detection
Crevat et al. (43) Low Unknown Low Unknown Low Low Unknown Unknown
Villar et al. (9) Low Low Low Low Low Low Unknown Low
Capeding et al. (18) Low Low Low Low Low Low Unknown Low
Amar-Singh et al. (40) High Low High Low Low Low Unknown High
Villar et al. (41) Low Low High Low Low Low Unknown High
Dayan et al. (37) Low Low High Low Low Low Unknown High
Leo et al. (38) Low Low High Low Low Low Unknown High
Tran et al. (39) Low Low High Low Low Low Unknown High
Sabchareon et al. (17) Low Low High Low Low Low Unknown High
Lanata et al. (42) Low Low Low Low Low Low Unknown Low
Risk of bias interpretation within trial bias Across trial bias
Low Bias, if present, is unlikely to alter 
the results seriously
Low risk of bias for all key domains Most information is from trials at low risk of bias
Unknown A risk of bias that raises some 
doubt about the results
Low or unclear risk of bias for all key 
domains
Most information is from trials at low or unclear risk of bias
High Bias may alter the results seriously High risk of bias for one or more key 
domains
The proportion of information from trials at high risk of 
bias is sufficient to affect the interpretation of results




Sample size Age range 
(years)
Males Outcome determined Seroprevalence at baseline







RCT (II) 60 30 1–1.25 63 60 Safety and immunogenicity DENV or JE; 45% DENV or JE; 50%
Villar  
et al. (9)
RCT (III) 12,574 6,261 9–16 49.7 49.6 Efficacy and safety DENV; 80% DENV; 77%
Capeding  
et al. (18)
RCT (III) 6,851 3,424 2–14 48 48 Efficacy and safety DENV or JE; 79% DENV or JE; 77%
Amar-Singh  
et al. (40)




RCT (II) 401 199 9–16 49.1 45.7 Safety and immunogenicity FV; 78.8% FV; 80.8%
Dayan  
et al. (37)
RCT (II) 100 50 9–16 40 55 Safety and immunogenicity DENV or YF; 81% DENV or YF; 84%
Leo  
et al. (38)
RCT (II) 898 300 2–17 44.0 54.4 Safety and immunogenicity Not stated Not stated
Tran  
et al. (39)
RCT (II) 120 60 2–17 48 58 Safety and immunogenicity DENV or JE; 71% DENV or JE; 78%
Sabchareon  
et al. (17)
RCT (IIb) 2,669 1,333 4–11 48 48 Efficacy, safety, and 
immunogenicity 
DENV or JE; 91% DENV or JE; 92%
Lanata  
et al. (42)
RCT (II) 199 99 2–11 51 46 Safety and immunogenicity DENV; 37% DENV; 48%
RCT, randomized controlled trial; DENV, dengue virus; YF, yellow fever; JE, Japanese encephalitis; FV, flavivirus.
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serotype, which was not statistically significant. The main find-
ings for CYD-TDV efficacy including evidence for the presence 
of heterogeneity and publication bias are summarized in Table 3.
CYD-TDv vaccine Safety
Generally, solicited injection site reactions (any) and solicited 
systemic reactions (any, fever, headache, and asthenia) showed 
an increased but statistically insignificant risk in vaccinated 
children compared with unvaccinated children. Other than the 
aforesaid, CYD-TDV vaccine reduced the risk of ARs. However, 
meta-analysis of included studies with longer follow-up time 
(25 months) revealed that CYD-TDV vaccination increased the 
risk of solicited injection site reactions; RR =  1.1 (1.04–1.17; 
p-value = 0.001) and RR = 1.09 (0.97–1.22; p-value = 0.145) using 
the fixed and random effects models, respectively. However, only 
the fixed model showed a statistically significant risk (Appendix 
TABLe 4 | Main CYD-TDV safety findings.








Harbord’s test for publication 
bias (p-value)
RR (95% Ci) p-value
SAE 7 783/24,304 447/12,020 0.0% (0.51) 0.52 0.86 (0.77–0.96) 0.009
Solicited reactionsa 2 133/299 110/149 0.0% (0.41) NA 0.64 (0.55–0.74) <0.001
UAE 7 1,709/4,239 847/2,003 18.7% (0.29) 0.02 0.95 (0.88–1.03) 0.19
Solicited injection site reactions occurring between day 0 and 7 post vaccination
Anya 5 2,112/3,935 898/1,848 61.4% (0.035) 0.64 1.06 (0.97–1.16) 0.2
Pain (any)a 3 151/663 191/329 52.2% (0.12) 0.48 0.40 (0.30–0.51) <0.001
Erythema (any) 5 72/1,140 50/504 67.1% (0.016) 0.42 0.55 (0.27–1.11) 0.09
Swelling (any) 5 50/1,140 41/504 67.2% (0.016) 0.37 0.47 (0.20–1.06) 0.07
Solicited systemic reaction occurring between day 0 and 14 post vaccination
Any 7 2,694/4,234 1,266/1,998 33.9% (0.17) 0.52 1.0 (0.95–1.06) 0.9
Fever (any) 5 187/1,138 75/504 48.1% (0.1) 0.94 1.08 (0.76–1.53) 0.67
Headache (any) 5 401/1,140 173/504 60.8% (0.03) 0.44 1.0 (0.78–1.3) 0.97
Malaise (any) 5 314/1,140 133/504 55.9% (0.059) 0.96 0.99 (0.75–1.32) 0.96
Myalgia (any) 5 312/1,140 158/504 68.0% (0.014) 0.788 0.8 (0.59–1.08) 0.15
Asthenia (any) 5 177/1,140 69/504 56.8% (0.055) 0.093 1.14 (0.75–1.74) 0.55
N, sample size; n, number of cases recorded; NA, not applicable (could not be calculated because few studies were pooled); SAE, severe adverse events; UAE, unsolicited adverse 
events.
aAll parameters were determined after resolving heterogeneity by excluding divergent studies.














RR (95% Ci) efficacy = (RR − 1)*100 
(95% Ci)
p-value
Overall 3 338/21,736 386/10,832 61.6% (0.074) 0.396 0.46 (0.36–0.60) 54% (40–64) <0.001
DENV1 3 126/21,736 126/10,832 0.0% (0.97) 0.482 0.50 (0.39–0.64) 50% (36–61) <0.001
DENV2 3 127/21,736 96/10,832 0.0% (0.45) 0.359 0.66 (0.51–0.86) 34% (14–49) 0.002
DENV3 3 54/21,736 107/10,832 0.0% (0.91) 0.062 0.25 (0.18–0.35) 75% (65–82) <0.001
DENV4 3 35/21,736 78/10,832 0.0% (0.61) NA 0.23 (0.15–0.34) 77% (66–85) <0.001
Unknown 
serotype
3 12/21,736 6/10,832 17.3% (0.3) NA 0.85 (0.26–2.74) 15% (−174–74) 0.79
N, sample size; n, number of cases recorded; NA, not applicable (could not be calculated because input data contained 0 values); DENV 1–4, dengue virus serotypes.
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IV, Figure 8 in Supplementary Material). Insignificantly increased 
risk of solicited systemic reactions was also observed using both 
the random and fixed effects models (Appendix IV, Figures 10 and 
11 in Supplementary Material). None of the aforementioned vari-
ables used in subgroup analyses were associated with finding of a 
statistically significant heterogeneity (I2 > 90%; p-value < 0.001). 
However, meta-regression analysis demonstrated that gender 
explained 95.1% (p-value = 0.049) and 96.5% (p-value = 0.002) 
of the variability in the studies that assessed solicited reactions 
and solicited injection site reactions, respectively (Appendix IV, 
Figures 2 and 3 in Supplementary Material). Negative gender 
coefficients entailed that for every unit increase in the propor-
tion of males in the CYD-TDV group, the log RR reduced by 
0.45 and 0.91 units for solicited reactions and injection site 
reactions, respectively. Following stratification of solicited reac-
tions and injection site reactions by gender, heterogeneity in the 
subgroups of the pooled studies with more males plummeted to 
0.0% (p-value < 0.41) and 61.4% (p-value = 0.035), respectively 
(Table 4). A study by Crevat et al. found that the most frequently 
reported safety profiles in the intervention group were UAEs 
(60–70%), solicited ARs (50–55%), solicited systemic reactions 
(40–50%), and solicited injection site reactions (<20%) (43). 
There were no immediate AEs or SAEs reported.
CYD-TDv vaccine induced 
immunogenicity
Although it was challenging to determine the overall immuno-
genicity using the random effects model due to the persistence of 
variation in the effect sizes even after resolving serotype-specific 
heterogeneity, the fixed effects model generated 74.28 1/dil 
(69.90–78.68; p-value < 0.001). The combined serotype-specific 
GMT levels found after resolving heterogeneity in descending 
order was: DENV3 (439.7 1/dil), DENV2 (323 1/dil), DENV1 
(144.1 1/dil), and DENV4 (105.71 1/dil). A different order was 
detected when the fixed effects model was applied; DENV3 
(114.56 1/dil), DENV4 (112.34 1/dil), DENV2 (81.91 1/dil), and 
DENV1 (40.51 1/dil) (Appendix IV in Supplementary Material). 
This showed that the estimates of immunogenicity were not 
robust. Subgroup analysis and the systematic elimination of 
studies with divergent mean differences revealed that combining 
studies with different ages resulted in significant heterogeneity, 
except for DENV1. This was observed even within the same 
TABLe 5 | Main CYD-TDV immunogenicity findings.
Dengue 
serotype




egger’s test for publication bias 
(p-value)
wMD expressed as gMTs  
(95% Ci)
p-value
DENV1 6 93.8% (<0.001) 0.01 107.5 (70.1–144.9) <0.001
DENV1a 5 11% (0.34) 0.11 144.1 (117.9–170.2) <0.001
DENV2 6 95.4% (<0.001) 0.007 176.9 (115.4–238.4) <0.001
DENV2a 3 14.9% (0.31) 0.53 323.1 (247–398.7) <0.001
DENV3 6 95.2% (<0.001) 0.013 221.9 (152.6–291.2) <0.001
DENV3a 3 41.6% (0.18) 0.5 439.7 (331.7–547.7) <0.001
DENV4 6 94.4% (<0.001) 0.04 152.9 (110.6–195.3) <0.001
DENV4a 3 37.4% (0.2) 0.65 105.7 (88.7–122.8) <0.001
WMD, weighted mean difference expressed as GMTs; GMTs, geometric mean titers (1/dil); DENV 1–4, dengue virus serotypes.
aAll parameters were determined after resolving heterogeneity by excluding divergent studies.
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study (Appendix IV, Figures 4 and 5 in Supplementary Material). 
By contrast, pooling together studies with the same age resulted 
in low heterogeneity (I2 = 0.0%), except for DENV4 (Appendix 
IV, Figures 6 and 7 in Supplementary Material). The main immu-
nogenicity findings and respective 95% CIs are summarized in 
Table 5. The highest neutralizing antibody titers in descending 
order reported by Cravat et al. were as follows: DENV3 (311–387 
1/dil), DENV2 (147–213 1/dil), DENV4 (127–160 1/dil), and 
DENV1 (105–124 1/dil) (43). Tran et al. reported the following 
GMTs: DENV1—4:129, 216, 169, and 146 1/dil, respectively (39). 
The study further demonstrated that GMTs in children increased 
with increasing age: 2–5  years (64.7–143 1/dil), 6–11  years 
(93.9–185 1/dil) and 12–17 years (135–334 1/dil).
DiSCUSSiON
CYD-TDv vaccine efficacy
Although our findings show that CYD-TDV vaccine is protec-
tive against dengue infection overall, its reduced efficacy against 
DENV2 is extremely worrying. This is because DENV2 is known 
to cause severe dengue infection and is twice as likely to result in 
DHF/DSS compared to other serotypes (6). The Asian DENV2 
has also been reported to cause outbreaks of DHF/DSS, highly 
pathogenic and is gradually replacing the less pathogenic Latin 
American variant (44). All efficacy studies conducted in Asia 
demonstrated reduced and statistically insignificant vaccine 
efficacy against DENV2 compared with the one conducted in 
Latin America. This might indicate that CYD-TDV vaccine 
induced antibodies readily neutralize the less pathogenic Latin 
American than the highly virulent Asian DENV2 variant. It has 
been reported that DENV2 neutralizing antibodies induced after 
primary infection with DENV1 demonstrate differential neutral-
izing activity against the Asian and Latin American DENV2 
variants (45).
It is worth noting that the observed 32% CYD-TDV vaccine 
protection against DENV2 is merely the best estimate. The real 
vaccine efficacy in the population can be as low as 14% (Table 3). 
Another important point to note is that CYD-TDV vaccine 
induced DENV2 neutralizing antibodies had the second highest 
GMT levels and yet provided the least protection. The question 
is why? Villar et al. concluded that GMT levels elicited by CYD-
TDV vaccine do not reflect serotype-specific vaccine efficacy (9). 
It has also been suggested that dengue antibodies either might 
not be the immunological correlate of protection or that each 
dengue serotype has its own protective titer threshold (46). Both 
findings correspond with our results which show that CYD-TDV 
vaccine protection was highest for the serotype with the lowest 
GMT levels and so on (Tables 3 and 5). Microevolution due to 
genetic recombination and natural selection occurring within 
individual dengue serotypes might explain lower efficacy of the 
CYD-TDV vaccine against DENV2 (47–49). Wahala et al. have 
shown that mutations occurring in the E protein (the major target 
for dengue neutralizing antibodies) have an effect on antibody 
binding and neutralizing activity (50). Therefore, reduced vac-
cine efficacy against DENV2 could be due to the fact that the 
circulating DENV2 virus acquired mutations in the E protein 
hence becoming antigenically and genetically different from the 
one included in the CYD-TDV vaccine. Reduced DENV2 vaccine 
efficacy might as well be as a result of dominant CYD-TDV vac-
cine induced antibodies that lack or have low serotype-specific 
neutralizing activity against the circulating DENV2 serotype. 
This is because high levels of serotype-specific neutralizing 
antibodies are known to confer protection against subsequent 
DENV infection (45). Evidence depicting a similar situation can 
be derived from the seasonal influenza vaccine which was only 
23% effective in vaccinees that were infected with a subtype that 
was different from the one included in the vaccine (51). Although 
information regarding the unknown DENV serotype is limited, a 
study by Mustafa et al. has proposed the emergence of a DENV5 
serotype (48). By contrast, Hesse argues that the aforesaid is 
highly unlikely because DENV mutation rate is too low to lead to 
the creation of a new serotype (44).
CYD-TDv vaccine Safety
Our overall findings regarding the safety of CYD-TDV vaccine 
are in agreement with the findings by da Costa et al. (16) in that 
none of the increased AEs and ARs were statistically significant. 
Crevat et  al. also concluded that CYD-TDV vaccine does not 
increase the risk of AEs and ARs in children below 2 years (43). 
However, this study had a small sample size (N =  90), short 
follow-up time (18 months), and it is not clear how allocation 
concealment was done. All of which might lead to the actual 
effect of CYD-TDV vaccine being overestimated. Contrary to 
the aforesaid, revelations from meta-analysis of studies with 
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longer follow-up time indicate that CYD-TDV increases the risk 
of injection site reactions significantly thus making it difficult 
to reject the pre-specified hypothesis (Appendix IV, Figure 8 
in Supplementary Material). Similarly, post  hoc analysis of the 
data from Capeding et  al. (18) has demonstrated that the risk 
of hospitalization and severe dengue in children aged between 
2 and 5 years vaccinated with CYD-TDV was highly significant 
(RR =  7.45: 1.15–313.8, p-value not provided) (52). However, 
post hoc meta-analysis of all studies conducted to assess CYD-
TDV vaccine safety in children is required before a comprehen-
sive conclusion can be made.
CYD-TDv vaccine induced 
immunogenicity
Our immunogenicity findings show that GMTs significantly 
increased in CYD-TDV vaccinated compared to unvaccinated 
children. Children in Latin America had higher GMT levels 
compared to those in Asia. Da Costa et al. (16) have reported 
similar results and evidence from our findings is sufficient to 
reject the pre-specified null hypothesis. However, there was 
significant variation in the effect sizes presented in the included 
studies. Interestingly, reduced heterogeneity was observed 
when studies with the same age group were combined regardless 
of study location except for DENV4. By contrast, combining stud-
ies with different age groups resulted in significantly increased 
heterogeneity regardless of study location and, surprisingly, 
even within the same study. Furthermore, we found that GMT 
effect sizes increased as the age of study participants increased, 
which corresponds with the findings by Tran et al. (39). Taken 
together, our findings clearly demonstrate that age influences 
CYD-TDV vaccine induced GMT levels. Included studies 
demonstrated that prior exposure to dengue viruses increased 
antibody response during subsequent infection. The observed 
variations in GMT levels among the included studies might be 
explained by variations in the burden of dengue infection across 
countries and between the two regions, with Asian countries 
experiencing a higher burden compared with Latin American 
countries (53). Although the PRNT is considered the gold 
standard, discrepancies between laboratories and regions have 
been reported (54, 55). Furthermore, the scientific community 
has different views regarding this test. Rainwater-Lovett et  al. 
and Thomas et  al. have separately reported that PRNT gives 
varying results based on the test conditions applied (56, 57). 
Endy has described as confusing the fact that PRNT does not 
give information on whether an individual will be protected 
from subsequent dengue infection using cross-reactive neutral-
izing antibodies (58). The former concern might be responsible 
for the observed variations in CYD-TDV vaccine elicited GMT 
levels across the included studies, while the later may be more 
applicable to the reduced vaccine efficacy against DENV2 as 
stated above. To the contrary, Timiryasova et al. have concluded 
that the PRNT test is fit for purpose and can “detect and measure 
dengue serotype-specific neutralizing antibodies in human 
serum samples with acceptable intra-assay and inter-assay pre-
cision, accuracy/dilutability, specificity, and with a lower limit 
of quantitation of 10” (59).
Strengths and Limitations
This, to the best of our knowledge, is the first systematic review to 
assess CYD-TDV vaccine efficacy not only in children exclusively 
but also using primary studies that were designed specifically to 
determine vaccine efficacy. Our review has demonstrated that 
children of varying ages respond to CYD-TDV vaccination differ-
ently and gender imbalance in the CYD-TDV group introduces 
heterogeneity when assessing solicited reactions and injection 
site reactions. Excluding graphically presented data prevented 
estimation bias. Since all of the included studies were conducted 
in children located in Asia and Latin America, the findings can-
not be generalized to children of all endemic regions.
implications for Public Health and 
Research
Emergence of novel and virulent dengue serotypes has been pro-
posed. To prevent possible pandemics, there is need to strengthen 
vector control programs, dengue surveillance, diagnostic capa-
bilities and management, and research through capacity building 
in endemic settings such as Asia, Latin America, and especially 
Africa, where dengue infection happens to be neglected (60, 61). 
DENV2 included in the CYD-TDV vaccine needs to be updated 
to match the currently circulating Asian and Latin American 
variants. In addition, understanding of dengue neutralizing anti-
bodies by investigating whether they are correlates of protection 
and what titer thresholds against all four serotypes are optimal 
for protection is warranted. Therefore, the scientific community 
needs to quickly come to a consensus regarding the PRNT test. 
Otherwise, new serological tests capable of being standardized 
to enable inter laboratory comparability, reproducibility and 
that can accurately and specifically measure dengue correlates of 
protection must be developed given that this is crucial for vaccine 
development. The fact that dengue infection is known to cause 
DHF/DSS and death in children is an indication that passive 
immunotherapy using serotype-specific neutralizing monoclonal 
antibodies that target conserved regions of the E protein might be 
a viable alternative to vaccination. Passive immunotherapy might 
significantly benefit younger children who are at higher risk and 
yet respond poorly to vaccines immunologically. Another reason 
for considering passive immunotherapy is that higher titers of 
serotype-specific neutralizing monoclonal antibodies can be 
administered without enhancing ADE, which is mainly caused 
by low titer levels of cross-reactive antibodies as previously 
mentioned. Future vaccine trials should consider employing 
≥25  months follow-up time, stratify and provide age specific 
data to facilitate comprehensive and conclusive analyses. Finally, 
post hoc analysis can reveal vital vaccine-related safety informa-
tion missed during the duration of the clinical trial. Therefore, the 
aforementioned analysis should be considered and encouraged 
where complete clinical data of participants involved in clinical 
trials are available.
CONCLUSiON
Overall, CYD-TDV vaccine is effective, but less efficacious 
against DENV2 in children. CYD-TDV vaccine is immunogenic 
in children with lower GMT levels observed in younger children 
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compared to adolescents. Although the vaccine increased the risk 
of some safety parameters in vaccinated children insignificantly, 
meta-analysis of studies with long follow-up time revealed that 
CYD-TDV vaccine significantly increased the risk of solicited 
injection site reactions. Therefore, post  hoc meta-analysis of 
the long term follow-up data (≥25 months) collected from the 
children previously vaccinated with CYD-TDV are needed before 
a comprehensive conclusion regarding CYD-TDV vaccine safety 
in children can be made. However, given the urgency for a dengue 
vaccine in endemic regions, CYD-TDV should be considered for 
use in regions where DENV2 is not endemic as currently there is 
no specific treatment for dengue infection.
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